Mackram F. Eleid, David R. Holmes Jr.
Index: 10.1146/annurev-med-101615-020427
Full Text: HTML
Transcatheter aortic valve replacement (TAVR) is a transformational and rapidly evolving treatment for patients with aortic stenosis who require valve replacement. Novel technological advancements have made this percutaneous minimally invasive therapy a first-line treatment for many patients at extreme risk for conventional cardiac surgery. New devices and improvements in existing devices have reduced procedural complications, and scientific trials are investigating the role of TAVR in lower-risk aortic stenosis populations, in patients with aortic regurgitation, and in patients with bicuspid aortic valve disease. Finally, there is intense interest in identifying patients in whom the risk-benefit ratio of TAVR is not favorable and should not be performed.
|
Gene Editing: A New Tool for Viral Disease
2017-01-18 [10.1146/annurev-med-051215-031129] |
|
The Type I Interferonopathies
2017-01-18 [10.1146/annurev-med-050715-104506] |
|
Esophageal Adenocarcinoma: Screening, Surveillance, and Mana...
2017-01-18 [10.1146/annurev-med-050715-104218] |
|
Management of Rectal Cancer Without Radical Resection
2017-01-18 [10.1146/annurev-med-062915-021419] |
|
The End of Nihilism: Systemic Therapy of Advanced Non–Small ...
2017-01-18 [10.1146/annurev-med-042915-102442] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2026 ChemSrc All Rights Reserved